Moderna Missed Expectations

Moderna (MRNA) reported a loss of $1.97 per share on revenue of $145.00 million for the second quarter ended June 2026. The consensus estimate was a loss of $1.97 per share on revenue of $126.65 million. The Earnings Whisper number was a loss of $1.54 per share. The company missed expectations by 27.92% while revenue grew 2.11% on a year-over-year basis.

Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale.